Date of Award
Master of Physician Assistant Studies
Physician Assistant Education
Type 2 diabetes is a disease plaguing the American population, bringing along with it a number of complications. With millions of dollars spent annually to care for diabetic patients and the complications of diabetes, much remains to be known regarding newer medications and the effects of those complications. Two sodium glucose co-transporter 2 inhibitors, canagliflozin and empagliflozin, and one glucagon-like peptide-1 receptor agonist, liraglutide, have proven cardiovascular benefit; however, their use in combination with metformin has not been well studied when compared to metformin and sulfonylurea therapy. While there are studies underway evaluating such outcomes, a critical review of current literature has revealed a lack of research to aid in the decision-making process of type 2 diabetes treatment.
Lucas, Brendan K., "Type 2 Diabetes: Cardiovascular Outcomes with Metformin and Incretin Combination Therapy Compared to Metformin and Sulfonylureas" (2019). Physician's Assistant Program Capstones. 30.